Scarica l'app Stockscreener
16.64
3.94%
0.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating - MSN
Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock - Investing.com
Beam Therapeutics (BEAM) Gets a Buy from Bernstein - The Globe and Mail
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Cathie Wood's ARK Invest ETFs Buy $46.2M in Biotech Stocks, Trim Defense Exposure - AInvest
Technical signs of recovery in Beam Therapeutics Inc.July 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Using data tools to time your Beam Therapeutics Inc. exitWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
Measuring Beam Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Smart Investment Allocation Tips - Newser
What does recent volatility data suggest for Beam Therapeutics Inc.July 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
Is Beam Therapeutics Inc. stock bottoming outJuly 2025 Outlook & Daily Momentum Trading Reports - Newser
Beam Therapeutics: Navigating Risks and Innovation in Gene Editing - AInvest
Beam Therapeutics: A Slow-Developing Story (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics Inc. stock prediction for this weekEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - Newser
Evaluating Beam Therapeutics Inc. with trendline analysisTrade Entry Report & Fast Entry High Yield Stock Tips - Newser
Should you hold or exit Beam Therapeutics Inc. nowEarnings Performance Report & AI Powered Market Entry Strategies - Newser
Will Beam Therapeutics Inc. rebound enough to break evenMarket Performance Summary & Weekly Setup with High ROI Potential - Newser
Is Beam Therapeutics Inc. a strong candidate for buy and hold2025 Earnings Impact & Detailed Earnings Play Strategies - thegnnews.com
Understanding Beam Therapeutics Inc.’s price movement2025 Momentum Check & Free Community Consensus Stock Picks - Newser
Is Beam Therapeutics Inc. likely to announce a buybackMarket Trend Report & Short-Term High Return Strategies - sisa-n.com
Applying Wyckoff theory to Beam Therapeutics Inc. stockDollar Strength & Risk Managed Investment Strategies - Newser
Chart overlay techniques for tracking Beam Therapeutics Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Is Beam Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideJuly 2025 Action & Free Growth Oriented Trading Recommendations - Newser
FMR LLC Boosts Stake in Beam Therapeutics Amidst Financial Challenges - AInvest
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics announces U.S. FDA granted RMAT to BEAM-101 - TipRanks
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com India
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics up after FDA's tag for sickle cell therapy - TradingView
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Unlocking 100%+ Upside: Top Analysts Reveal Small-Cap Stocks to Double Your Money - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Applying Elliott Wave Theory to Beam Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Has Beam Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewDaily Market Momentum Summary and Strategy - Newser
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
Cantor Fitzgerald Issues Negative Outlook for BEAM Earnings - Defense World
Using flow based indicators on Beam Therapeutics Inc.Free Fast Exit and Entry Strategy Guide - Newser
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
William Blair Lifts Earnings Estimates for Beam Therapeutics - Defense World
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Leerink Partners Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Beam Therapeutics Receives Buy Rating from Leerink Partners with $42 Price Target - AInvest
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):